Virulent Bacteriophages for Controlling Shiga Toxin–Producing Escherichia coli Without Inducing Toxin Production
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiaf035 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Eunshin Cho und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food and Animal Biotechnology, Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Escherichia coli Infections, Shiga-Toxigenic Escherichia coli, Bacteriophages, Escherichia coli O157. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Shiga toxin–producing Escherichia coli (STEC) infections pose a significant public health challenge, characterized by severe complications including hemolytic uremic syndrome (HUS) due to Shiga toxin (Stx) production. Current therapeutic approaches encounter a critical limitation, as conventional antibiotic treatment is contraindicated due to its propensity to trigger bacterial SOS response and subsequently enhance Stx production, which increases the likelihood of developing HUS in antibiotic-treated patients. The lack of effective, safe therapeutic options has created an urgent need for alternative treatment strategies for STEC infections. This study investigates the therapeutic potential of virulent bacteriophages (phages) against STEC O157:H7. Our findings demonstrate that these phages effectively reduce STEC populations to levels comparable to ciprofloxacin treatment, while crucially avoiding the induction of SOS response and subsequent enhancement of Stx production. This is a significant advantage over conventional antibiotics, which increase Stx levels. Furthermore, these phages exhibited broad-spectrum antimicrobial activity against multiple clinical STEC isolates without triggering toxin expression. The capability of virulent phages to effectively control STEC without enhancing toxin production represents a promising therapeutic strategy that combines antimicrobial efficacy with safety considerations. These characteristics indicate that virulent phages represent a potential solution to address the current therapeutic challenges in STEC infections, particularly in mitigating the risk of HUS development in infected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Food and Animal Biotechnology, Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul, Republic of Korea.
- Department of Agricultural Biotechnology, Seoul National University, Seoul, Republic of Korea.
- Center for Food and Bioconvergence, Seoul National University, Seoul, Republic of Korea.
- Department of Food Science and Biotechnology, and Carbohydrate Bioproduct Research Center, Sejong University, Seoul, Republic of Korea.
- Division of Environmental Health Sciences, School of Public Health, University of Minnesota, St Paul, Minnesota, USA.
ORCID-Profile: Eunshin Cho, Jinshil Kim, Sangryeol Ryu, Byeonghwa Jeon
Zitieren
APA
Cho, E., Kim, J., Won, T., Ryu, S., & Jeon, B. (2026). Virulent Bacteriophages for Controlling Shiga Toxin–Producing Escherichia coli Without Inducing Toxin Production. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf035
Vancouver
Cho E, Kim J, Won T, Ryu S, Jeon B. Virulent Bacteriophages for Controlling Shiga Toxin–Producing Escherichia coli Without Inducing Toxin Production. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf035
BibTeX
@article{Cho2026,
author = {Cho, Eunshin and Kim, Jinshil and Won, Taehee and Ryu, Sangryeol and Jeon, Byeonghwa},
title = {Virulent Bacteriophages for Controlling Shiga Toxin–Producing Escherichia coli Without Inducing Toxin Production},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiaf035}
}
EUVIMED